W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
13,590 pages, 4,139,114 edits & 37,811,477 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Information about Dinutuximab

Dinutuximab is a recombinant chimeric monoclonal antibody to GD2 which is used as an anticancer agent in combination with other antineoplastic agents in the treatment of neuroblastoma. 

Liver safety of Dinutuximab

Transient asymptomatic elevations in serum aminotransferase levels are common during dinutuximab therapy, but it has not been linked to instances of clinically apparent liver injury

Mechanism of action of Dinutuximab

Dinutuximab (din" ue tux' i mab) is a mouse-human chimeric monoclonal IgG1 antibody to disialoganglioside (GD2), a cell surface glycolipid that is present in low concentrations on skin, neural or peripheral nerve cells and is overexpressed on neuroblastoma cells.  Engagement of dinutuximab with GD2 triggers antibody dependent cell cytotoxicity.  Cytotoxicity of dinutuximab is increased by coadministration of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin 2 (IL2) because of their effects on neutrophils, macrophages and immune effector cells, for which reason dinutuximab is usually combined with these cytokines. 

FDA approval information for Dinutuximab

Dinutuximab was approved for use in neuroblastoma in the United States in 2015.  Current indications are for its administration with IL2 or GM-CSF added to standard isotretinoin therapy of high risk pediatric patients with neuroblastoma. 

Dosage and administration for Dinutuximab

Dinutuximab is available in liquid solution in single use vials of 17.5 mg in 5 mL (3.5 mg/mL) under the brand name Unituxin.  Dinutuximab is given by slow intravenous infusion (over 10 hours) in a dose of 17.5 mg/m2 daily for 4 consecutive days, repeated in up to 5 cycles.  Premedication with hydration, diphenhydramine, acetaminophen and a potent analgesic [such as morphine] is recommended. 

Side effects of Dinutuximab

Adverse side effects of the combination immunotherapy are frequent and can be severe.  These side effects include infusion reactions, nausea and vomiting, rash, hypotension, capillary leak syndrome, neuropathic pain and peripheral neuropathy.  Less common, but potentially severe side effects include severe hypersensitivity reactions, neurologic and ophthalmologic toxicities, transverse myelitis, reversible posterior leukoencephalopathy syndrome, severe infections, bone marrow suppression, electrolyte abnormalities and embryo-fetal toxicity.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Dinutuximab

Reviews for Dinutuximab

Learn more about Dinutuximab

Latest research - Dinutuximab

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Dinutuximab is a stub. If you are familiar with the topic Dinutuximab, you can help us. Paid editors welcome!


Dinutuximab is part of WikiMD's free ^articles!

^Dinutuximab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available